Review



il 17 a  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems il 17 a
    Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001
    Il 17 A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 17 a/product/R&D Systems
    Average 94 stars, based on 13 article reviews
    il 17 a - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "Mitochondria-targeted nanozyme system for psoriasis treatment"

    Article Title: Mitochondria-targeted nanozyme system for psoriasis treatment

    Journal: Journal of Nanobiotechnology

    doi: 10.1186/s12951-026-04068-z

    Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001
    Figure Legend Snippet: Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001

    Techniques Used: Staining, Colorimetric Assay, Activity Assay, Expressing, Marker, Enzyme-linked Immunosorbent Assay



    Similar Products

    93
    MedChemExpress mouse il 17a f protein
    <t>IL-17A/F</t> <t>represses</t> <t>ECs</t> Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.
    Mouse Il 17a F Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse il 17a f protein/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mouse il 17a f protein - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    94
    R&D Systems il 17 a
    Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001
    Il 17 A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 17 a/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    il 17 a - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems hil 17af
    Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001
    Hil 17af, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hil 17af/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    hil 17af - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems rat il 17af
    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and <t>rat</t> <t>IL-17AF</t> as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.
    Rat Il 17af, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat il 17af/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    rat il 17af - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    86
    Novartis il 17a f
    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and <t>rat</t> <t>IL-17AF</t> as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.
    Il 17a F, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 17a f/product/Novartis
    Average 86 stars, based on 1 article reviews
    il 17a f - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    94
    R&D Systems interleukin 17
    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and <t>rat</t> <t>IL-17AF</t> as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.
    Interleukin 17, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/interleukin 17/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    interleukin 17 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    93
    R&D Systems heterodimer il 17a f
    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and <t>rat</t> <t>IL-17AF</t> as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.
    Heterodimer Il 17a F, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/heterodimer il 17a f/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    heterodimer il 17a f - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant human cytokine il 17 a f
    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and <t>rat</t> <t>IL-17AF</t> as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.
    Recombinant Human Cytokine Il 17 A F, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human cytokine il 17 a f/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    recombinant human cytokine il 17 a f - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    Image Search Results


    IL-17A/F represses ECs Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IL-17A/F represses ECs Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Western Blot, Comparison, Quantitative RT-PCR

    IL-17A/F counteracts Endothelial Ido1 overexpression-induced neovascularization under conditions of lower limb ischemia. (A) Scheme showing the experiment for rescuing the IL-17A/F-treated young mice by endothelial Ido1 overexpression. (B and C) Representative laser Doppler images (B) of hindlimbs of mice and quantification (C) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in AAV-NC + PBS, AAV-NC + IL-17A/F, AAV- Ido1 + PBS and AAV- Ido1 + IL-17A/F mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗AAV-NC + IL-17A/F vs. AAV-NC + PBS; # AAV- Ido1 + IL-17A/F vs. AAV-NC+ IL-17A/F, #/ ∗ P < 0.05, ### P < 0.001, ∗∗∗∗/ #### P < 0.0001. (D) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (E) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (G) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (H) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (I) Quantification of the CD31-positive area in muscle. One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Journal: Redox Biology

    Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

    doi: 10.1016/j.redox.2025.103695

    Figure Lengend Snippet: IL-17A/F counteracts Endothelial Ido1 overexpression-induced neovascularization under conditions of lower limb ischemia. (A) Scheme showing the experiment for rescuing the IL-17A/F-treated young mice by endothelial Ido1 overexpression. (B and C) Representative laser Doppler images (B) of hindlimbs of mice and quantification (C) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in AAV-NC + PBS, AAV-NC + IL-17A/F, AAV- Ido1 + PBS and AAV- Ido1 + IL-17A/F mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗AAV-NC + IL-17A/F vs. AAV-NC + PBS; # AAV- Ido1 + IL-17A/F vs. AAV-NC+ IL-17A/F, #/ ∗ P < 0.05, ### P < 0.001, ∗∗∗∗/ #### P < 0.0001. (D) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (E) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (G) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (H) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (I) Quantification of the CD31-positive area in muscle. One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

    Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

    Techniques: Over Expression, Comparison, Micro-CT, Immunofluorescence, Staining, Muscles

    Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001

    Journal: Journal of Nanobiotechnology

    Article Title: Mitochondria-targeted nanozyme system for psoriasis treatment

    doi: 10.1186/s12951-026-04068-z

    Figure Lengend Snippet: Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001

    Article Snippet: Cytokine levels in cell culture supernatants and tissue homogenates were measured using ELISA kits for IL-1β (DY401), IL-6 (M6000B), TNF-α (MTA00B), IL-17 A (DY5390), and IL-23 (M2300) (R&D Systems, USA).

    Techniques: Staining, Colorimetric Assay, Activity Assay, Expressing, Marker, Enzyme-linked Immunosorbent Assay

    (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and rat IL-17AF as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.

    Journal: PLOS One

    Article Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis

    doi: 10.1371/journal.pone.0341049

    Figure Lengend Snippet: (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and rat IL-17AF as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.

    Article Snippet: To determine cellular potency, recombinant human (h)IL-17AA (Genscript cat# Z03228), hIL-17AF (R&D cat# 5837-IL-010), hIL-17FF (R&D Systems 1335-IL), rat IL-17AA (R&D systems 8410-IL-025), and rat IL-17AF (R&D systems 9340-IL-025) were used for in vitro stimulation at the concentrations listed in .

    Techniques: Inhibition, Sampling, Concentration Assay